Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunrest LifescienceNSE:SUNREST -5.59%42 EV-to-EBIT is 4.97 as of Aug. 27, 2026, which is 59% below its 10-year median of 12.01. GuruFocus rates NSE:SUNREST with a GF Score™ of 42/100. The stock has 6 warning signs investors should review. Among 480 Healthcare Providers & Services companies, Sunrest Lifescience ranks better than 90.21% on this metric.
The historical rank and industry rank for Sunrest Lifescience's EV-to-EBIT or its related term are showing as below:
NSE:SUNREST'
s EV-to-EBIT Range Over the Past 10 Years
Min: 3.34 Med: 12.01 Max: 39.61
Current: 4.98
During the past 7 years, the highest EV-to-EBIT of Sunrest Lifescience was 39.61. The lowest was 3.34. And the median was 12.01.
NSE:SUNREST's EV-to-EBIT is ranked better than 90.21% of 480
companies
in the Healthcare Providers & Services industry
Industry Median: 15.75
vs NSE:SUNREST: 4.98
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sunrest Lifescience's Enterprise Value for the quarter that ended in Mar. 2026 was ₹416.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunrest Lifescience's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹87.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunrest Lifescience EV-to-EBIT Related Terms
Sunrest Lifescience EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sunrest Lifescience's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Sunrest Lifescience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunrest Lifescience EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sunrest Lifescience's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sunrest Lifescience's EV-to-EBIT falls into.
Sunrest Lifescience's current Enterprise Value is ₹434.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunrest Lifescience's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹87.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunrest Lifescience (NSE:SUNREST) has a EV-to-EBIT of 4.97 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sunrest Lifescience and its competitors. This is 59% below median its historical median of 12.01. Over the past decade, Sunrest Lifescience's EV-to-EBIT has ranged from 3.34 to 39.61. According to the industry distribution chart, Sunrest Lifescience ranks #47 out of 480 companies in the Healthcare Providers & Services industry, placing it in the top 9.8%.
Is Sunrest Lifescience's EV-to-EBIT too high?
Sunrest Lifescience's current EV-to-EBIT of 4.97 is 59% below median its 10-year median of 12.01. Over the past 10 years, this metric has ranged from a low of 3.34 to a high of 39.61. The Healthcare Providers & Services industry median EV-to-EBIT is 15.75. Sunrest Lifescience's value of 4.97 is 68.4% below this industry median. Based on the distribution chart, Sunrest Lifescience ranks #47 out of 480 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sunrest Lifescience has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's EV-to-EBIT compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sunrest Lifescience ranks #47 out of 480 companies for EV-to-EBIT. This places Sunrest Lifescience in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.75. Sunrest Lifescience's value of 4.97 is 68.4% below this benchmark. Historically, Sunrest Lifescience's own EV-to-EBIT has ranged from 3.34 to 39.61 over the past decade. While the company's 10-year median is 12.01 vs. the industry median of 15.75, Sunrest Lifescience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.75, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunrest Lifescience's current EV-to-EBIT of 4.97 is 68.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sunrest Lifescience and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunrest Lifescience's current EV-to-EBIT is 4.97, which is 59% below median its own 10-year median of 12.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current EV-to-EBIT of 4.97. The current EV-to-EBIT is 4.97, which is 59% below median its 10-year median of 12.01 and 68.4% below the Healthcare Providers & Services industry median of 15.75. Sunrest Lifescience's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current EV-to-EBIT is 4.97 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
42GF Score
Get the complete analysis for NSE:SUNREST
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUNREST has been successfully added to your 
